Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp.
Your view on TNXP
Overview
What the company does, where it operates, and who runs it.
About Tonix Pharmaceuticals Holding Corp.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Seth Lederman
- Headquarters
- 26 Main Street, Chatham, NJ, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Seth Lederman
- Headquarters
- 26 Main Street, Chatham, NJ, US
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering.
Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates.
The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases.
Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome.
The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition.
Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication.
The company was founded in 2007 and is headquartered in Chatham, New Jersey.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Tonix Pharmaceuticals Holding Corp., and the rating behind it. TNXP last traded at $11.87; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Tonix Pharmaceuticals Holding Corp.. Starting points for Tonix Pharmaceuticals Holding Corp.: EPS -$9.60, beta 1.75 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Tonix Pharmaceuticals Holding Corp.. Tonix Pharmaceuticals Holding Corp. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Tonix Pharmaceuticals Holding Corp.. Trailing twelve-month EPS for Tonix Pharmaceuticals Holding Corp. stands at -$9.60. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Tonix Pharmaceuticals Holding Corp.. Tonix Pharmaceuticals Holding Corp. has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Tonix Pharmaceuticals Holding Corp. valued side by side against its closest peers. Tonix Pharmaceuticals Holding Corp. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Tonix Pharmaceuticals Holding Corp., and how their positions are changing. At a $189.2M market value, institutional positions materially move Tonix Pharmaceuticals Holding Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Tonix Pharmaceuticals Holding Corp. executives and directors. Shares of Tonix Pharmaceuticals Holding Corp. have traded between $6.76 and $130.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Tonix Pharmaceuticals Holding Corp.. Tonix Pharmaceuticals Holding Corp. is a $189.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Tonix Pharmaceuticals Holding Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Tonix Pharmaceuticals Holding Corp.. Coverage tracks Tonix Pharmaceuticals Holding Corp. within Biotechnology (Healthcare). Press releases and market coverage, newest first.